A share price of Immunome Inc [IMNM] is currently trading at $19.37, up 13.34%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The IMNM shares have gain 5.85% over the last week, with a monthly amount glided 13.94%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Immunome Inc [NASDAQ: IMNM] stock has seen the most recent analyst activity on December 01, 2025, when Truist initiated its Buy rating and assigned the stock a price target of $36. Previously, Goldman started tracking the stock with Buy rating on September 22, 2025, and set its price target to $26. On September 05, 2025, Craig Hallum initiated with a Buy rating and assigned a price target of $26 on the stock. Lake Street started tracking the stock assigning a Buy rating and suggested a price target of $23 on April 02, 2025. Stephens initiated its recommendation with a Overweight and recommended $30 as its price target on November 08, 2024. Piper Sandler started tracking with a Overweight rating for this stock on May 31, 2024, and assigned it a price target of $27. In a note dated April 30, 2024, JP Morgan initiated an Overweight rating and provided a target price of $24 on this stock.
Immunome Inc experienced fluctuations in its stock price throughout the past year between $5.15 and $19.16. Currently, Wall Street analysts expect the stock to reach $28.25 within the next 12 months. Immunome Inc [NASDAQ: IMNM] shares were valued at $19.37 at the most recent close of the market. An investor can expect a potential return of 45.84% based on the average IMNM price forecast.
Analyzing the IMNM fundamentals
Trailing Twelve Months sales for Immunome Inc [NASDAQ:IMNM] were 9.68M which represents -100.00% decline. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -17.84%, Pretax Profit Margin comes in at -16.87%, and Net Profit Margin reading is -16.87%. To continue investigating profitability, this company’s Return on Assets is posted at -0.72, Equity is -0.87 and Total Capital is -0.82. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.69 points at the first support level, and at 16.02 for the second support level. However, for the 1st resistance point, the stock is sitting at 20.35, and for the 2nd resistance point, it is at 21.33.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Immunome Inc [NASDAQ:IMNM] is 8.90. Further, the Quick Ratio stands at 8.90, while the Cash Ratio is 6.29. Considering the valuation of this stock, the price to sales ratio is 183.52, the price to book ratio is 6.73.
Transactions by insiders
Recent insider trading involved BIENAIME JEAN JACQUES, Director, that happened on Jun 03 ’25 when 5000.0 shares were purchased. Director, BIENAIME JEAN JACQUES completed a deal on Mar 25 ’25 to buy 7800.0 shares. Meanwhile, President and CEO SIEGALL CLAY B bought 0.14 million shares on Mar 26 ’25.
